title: Plutonium behavior after pulmonary administration according to solubility properties, and consequences on alveolar macrophage activation.
abstract: The physico-chemical form in which plutonium enters the body influences the lung distribution and the transfer rate from lungs to blood. In the present study, we evaluated the early lung damage and macrophage activation after pulmonary contamination of plutonium of various preparation modes which produce different solubility and distribution patterns. Whatever the solubility properties of the contaminant, macrophages represent a major retention compartment in lungs, with 42 to 67% of the activity from broncho-alveolar lavages being associated with macrophages 14 days post-contamination. Lung changes were observed 2 and 6 weeks post-contamination, showing inflammatory lesions and accumulation of activated macrophages (CD68 positive) in plutonium-contaminated rats, although no increased proliferation of pneumocytes II (TTF-1 positive cells) was found. In addition, acid phosphatase activity in macrophages from contaminated rats was enhanced 2 weeks post-contamination as compared to sham groups, as well as inflammatory mediator levels (TNF-α, MCP-1, MIP-2 and CINC-1) in macrophage culture supernatants. Correlating with the decrease in activity remaining in macrophages after plutonium contamination, inflammatory mediator production returned to basal levels 6 weeks post-exposure. The production of chemokines by macrophages was evaluated after contamination with Pu of increasing solubility. No correlation was found between the solubility properties of Pu and the activation level of macrophages. In summary, our data indicate that, despite the higher solubility of plutonium citrate or nitrate as compared to preformed colloids or oxides, macrophages remain the main lung target after plutonium contamination and may participate in the early pulmonary damage.
authors.affiliation: CEA/DSV/IRCM/SREIT, Laboratory of Radiotoxicology, Centre DAM-Ile de France, Arpajon cedex, France.
authors.forename: Anne
authors.initials: A
authors.lastname: Van der Meeren
authors.forename: Olivier
authors.initials: O
authors.lastname: Gremy
authors.forename: Daniel
authors.initials: D
authors.lastname: Renault
authors.forename: Amandine
authors.initials: A
authors.lastname: Miroux
authors.forename: Sylvie
authors.initials: S
authors.lastname: Bruel
authors.forename: Nina
authors.initials: N
authors.lastname: Griffiths
authors.forename: Françoise
authors.initials: F
authors.lastname: Tourdes
mesh_terms: D000280:Administration, Inhalation; D000818:Animals; D002478:Cells, Cultured; D018836:Inflammation Mediators / Q000276:immunology*; D008262:Macrophage Activation / Q000276:immunology* / Q000528:radiation effects*; D008297:Male; D011005:Plutonium / Q000008:administration & dosage / Q000737:chemistry* / Q000633:toxicity*; D011650:Pulmonary Alveoli / Q000737:chemistry / Q000276:immunology* / Q000528:radiation effects*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012995:Solubility
chemical_list: D018836:Inflammation Mediators; D011005:Plutonium